Personalized high-definition transcranial direct current stimulation is linked to improved outcomes in moderate-to-severe ...
A phase 2 trial suggests that the novel SNRI ammoxetine may effectively treat major depressive disorder while avoiding some side effects common to other antidepressants.
Atai Life Sciences (NASDAQ:ATAI) and Beckley Psytech Limited, a private clinical-stage biopharmaceutical company, released data from a proof-of-concept study investigating a two-dose induction regimen ...
MedPage Today on MSN
Novel Drug Fails to Outperform Common Treatment in Depression and Insomnia
An investigational drug did not significantly improve outcomes versus quetiapine extended release (Seroquel XR) as an ...
A new study shows that a personalized, precise form of brain stimulation, HD-tDCS, can rapidly ease depression symptoms – and ...
Electroacupuncture added to standard care improved sleep quality in people with depression-related insomnia, a randomized clinical trial showed. At 8 weeks, a -6.2 point change (95% CI -6.9 to -5.6) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback